


■ 99% or ◊ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 0.4$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{56} = 67.6$; $p > 0.1$; NS

Heterogeneity between 59 trials: $\chi^2_{58} = 68.0$; $p > 0.1$; NS

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.
 † Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◊ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 1.2$; $p > 0.1$; NS


Heterogeneity within subtotals: $\chi^2_{56} = 74.4$; $p = 0.05$

Heterogeneity between 59 trials: $\chi^2_{58} = 75.7$; $p = 0.06$

0 0.5 1.0 1.5 2.0
Polychemo. better | Polychemo. worse
Treatment effect 2p < 0.00001

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◊ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 2.2$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{46} = 31.1$; $p > 0.1$; NS

Heterogeneity between 49 trials: $\chi^2_{48} = 33.3$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse

Treatment effect 2p > 0.1; NS, adverse

§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◁ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 3.0$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{32} = 32.9$; $p > 0.1$; NS

Heterogeneity between 35 trials: $\chi^2_{34} = 35.8$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse

Treatment effect 2p > 0.1; NS, adverse

§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone




■ 99% or ◁▷ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 3.0$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{20} = 24.6$; $p > 0.1$; NS

Heterogeneity between 23 trials: $\chi^2_{22} = 27.6$; $p > 0.1$; NS



§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone

Year code and study name	Months & treatment	Deaths/woman-years Polychemo. deaths		Logrank Variance O-E	Ratio of annual death rates Polychemo. : Control
		Allocated polychemo.	Adjusted control		
(a) CMF regimens (including other non-anthracycline agents)					
73B INT Milan 7205	12 CMF	0/2127	0/1427		
75E2 Manchester I	12 CMF	0/434	0/436		
76C Glasgow	12 CMF	0/835	0/625		
76E EORTC 09771	24 CMF	0/1481	0/1233		
77B1+2 DanishBCG77bpre	12 CMF	0/2293	0/1741		
77G1 Vienna	36 CMFV	0/717	0/646		
78E UK/Asia Collab	124 CMF	0/1352	0/1178		
78K3 IBCSG/Ludwig III post	12 CMF	2/1414	1/1104	0.5 0.7	→
78V2 ECOG EST16177 post	12 CMFPr	0/566	0/599		
79B1 SWOG7827A poER+	12 CMFVPr	2/2614	1/2413	0.5 0.8	→
79C Case/WesternB ER+	12 CMFVPr	0/432	0/465		
79E Guy's/Manch. II	12 CMF	0/1575	0/1145		
79H Paris N-	6 CMF	-1/113	-985	(no data)	
80F INT Milan 8004 N-	12 CMF	0/589	0/358		
80J1 Vienna Gyn. post	† 6 CMF	0/194	0/223		
80L SWOG 7985	?? CMFV			(no data)	
81H EST1180/SW.8294	6 CMFPr	0/2851	0/2337		
82C DanishBCG82cpost	† 9 CMF	1/4464	0/4243	0.5 0.3	→
84D NCI-C MA.4	† 6 CMF	1/1828	0/1707	0.4 0.2	→
85J1+3 PetrovStPetersb'g	† 4 CMF; 2TtMF	0/1844	2/1704	-0.5 0.3	→
86H2 IBCSG VII *	† 3/6 CMF	0/5820	3(0/1804)		
87D3 GABG 3 Germany	† 6 CMF	-1/066	-916	(no data)	
88C NSABP B-20	† 2 CMF	0/6149	0/5921		
88D IBCSG IX	† 3 CMF	2/4391	0/4149	1.0 0.5	→
89A2 SITAM-01	† 6 CMF	0/287	0/277		
89E4+9 GROCTA V Italy	† 6 CMF	-2/16	-1/68	(no data)	
89J1 CRCRAMS Moscow	6 CMF	0/39	0/24		
89V Romagnolo Italy	6 CMF	0/800	0/781		
90P Amsterdam C8913	6 CMF	0/633	0/452		
90S1 IBCSG VIII	6 CMF			(no data)	
90X1 Tokyo CIH	6 CMF	0/611	0/634		
93S Hamburg, Germany Sweden-Finland	6 CMF 9 CMF	0/396	0/430		
(a) subtotal with data § *		8/ 46733	4/ 41664	2.4 2.7	2.44 (SE 0.98) increase 2p > 0.1; NS
(b) Anthracycline regimens					
74D1 DFCI 74-063 *	7/3.5 AC	0/47	2(0/17)		
76H1 West Midlands N+	6 CMFVAFol	0/1917	0/1409		
76L1 Cologne	?? AC			(no data)	
80B3+4 N Sweden BCG	† 8 AC	0/639	1/526	-0.4 0.2	→
80C2 SESwed.BCGB post	6 AC	0/233	1/169	-0.6 0.2	→
80S1 Helsinki	† 8 FAC	0/313	1/257		
80Z Wessex	† 6 FAP/VAC	0/452	0/391		
82F MD Anders.8227 N-	4 FAP/VP	0/446	0/407		
83B GROCTA I Italy ER+	† 6 CMF; 4 E	0/1474	0/1311		
84C NSABP B-16 post*	† 24 MeIF+A/3AC	0/6964	2(0/3102)		
84Q4+5 Austrian BCSG 4	† 6 CMFVA	-7/70	-765	(no data)	
86P2+3 FASG France	† 6 FEC	0/3187	0/2986		
89@ Bari Italy N-	6 FEC	0/644	0/539		
89B1 SWOG 8814 *	† 6 FAC	4/6923	4(1/2118)	0.1 0.9	→
89D IGR Paris	† 6 FAC/FEC	0/3408	0/3118		
90C6 FASG GFEA 07	† 6 FEC	0/649	0/603		
92D Amsterdam C9203	† 4 EC	0/179	0/178		
93H IBCSG 11-93 N+pre	† 4 AC	-3/07	-302	(no data)	
93M1+2 IBCSG 12-93 N+post	† 4 AC			(no data)	
94F JCOG 9401 N+post	† 6 AC	0/200	0/202		
(b) subtotal with data § *		4/ 27675	7/ 26806	-0.9 1.3	0.51 (SE 0.63) reduction 2p > 0.1; NS
(c) Other polychemotherapy					
73C1 Mayo 70-56-32	12 CFPPr	0/158	0/130		
74E UK MCCC 003	6 CVF/CVM	1/710	2/568	-0.6 0.7	→
75G Northwick Park	12 MeIV	0/550	0/601		
76H2 West Midlands N-	6 ChiMF	0/3692	0/3578		
76K HD 1 W. Germany	24 ChiF	-4/51	-372	(no data)	
76F King's CRC M/M	24 MeIM	0/799	0/726		
77E Oxford	24 MeIMF	0/776	0/599		
77W2 Montpellier	12 CVF			(no data)	
78M3 NCC13-773051 post	10 CFPPr	0/568	0/627		
81E NSABP B-13 N-	11 MFFol	0/3883	0/3416		
86D1 UK Multicentre	† 6 CVF/CVM	0/352	0/329		
88C NSABP B-20	† ?? MFFol	2/6156	0/5921	1.0 0.5	→
92B2 HE1092 Greece	† 6 CMzF	0/540	0/633		
93A1245 UKCCCR ABC	† various			(no data)	
(c) subtotal with data §		3/ 18184	2/ 17128	0.4 1.2	1.35 (SE 1.05) increase 2p > 0.1; NS
Total (a + b + c) *		15/ 92592	13/ 85598	1.9 5.3	1.436 (SE 0.523) increase 2p > 0.1; NS

■ 99% or ◁▷ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 2.2$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_8 = 6.9$; $p > 0.1$; NS

Heterogeneity between 11 trials: $\chi^2_{10} = 9.1$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse

Treatment effect $2p > 0.1$; NS, adverse

§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◁ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 2.3$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{29} = 25.2$; $p > 0.1$; NS

Heterogeneity between 32 trials: $\chi^2_{31} = 27.5$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse

Treatment effect 2p > 0.1; NS, adverse

§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◊ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 2.8$; $p > 0.1$; NS


Heterogeneity within subtotals: $\chi^2_{34} = 30.5$; $p > 0.1$; NS


Heterogeneity between 37 trials: $\chi^2_{36} = 33.3$; $p > 0.1$; NS


§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone







■ 99% or ◁▷ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 4.9$; $p = 0.09$

Heterogeneity within subtotals: $\chi^2_{11} = 12.0$; $p > 0.1$; NS

Heterogeneity between 14 trials: $\chi^2_{13} = 16.9$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse

Treatment effect $2p > 0.1$; NS, adverse

§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◁ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 0.3$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{32} = 25.6$; $p > 0.1$; NS

Heterogeneity between 35 trials: $\chi^2_{34} = 25.9$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse


Treatment effect 2p > 0.1; NS


§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone







Heterogeneity between 3 subtotals: $\chi^2 = 3.1$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{47} = 42.1$; $p > 0.1$; NS

Heterogeneity between 50 trials: $\chi^2_{49} = 45.2$; $p > 0.1$; NS


0 0.5 1.0 1.5 2.0
Polychemo. better | Polychemo. worse

Treatment effect $2p > 0.1$; NS

§ 9 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 943; allocated control: 880)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◊ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2 = 0.3$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{43} = 46.3$; $p > 0.1$; NS


Heterogeneity between 46 trials: $\chi^2_{45} = 46.7$; $p > 0.1$; NS

Treatment effect $2p = 0.05$

§ 13 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 5628; allocated control: 5211)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◊ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 0.7$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{26} = 22.9$; $p > 0.1$; NS

Heterogeneity between 29 trials: $\chi^2_{28} = 23.6$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse


Treatment effect 2p = 0.003

§ 13 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 2139; allocated control: 1562)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone





■ 99% or ◊ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 3.9$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{47} = 43.7$; $p > 0.1$; NS

Heterogeneity between 50 trials: $\chi^2_{49} = 47.6$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse

Treatment effect 2p > 0.1; NS, adverse

§ 9 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 4501; allocated control: 3963)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



■ 99% or ◁ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 0.8$; p > 0.1; NS

Heterogeneity within subtotals: $\chi^2_{24} = 23.3$; p > 0.1; NS

Heterogeneity between 27 trials: $\chi^2_{26} = 24.1$; p > 0.1; NS

0 0.5 1.0 1.5 2.0


Polychemo. better | Polychemo. worse

Treatment effect 2p > 0.1; NS

§ 9 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 4501; allocated control: 3963)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone



Year code and study name	Months & treatment	Events/woman-years Polychemo. events		Logrank Variance O-E	Ratio of annual event rates Polychemo. : Control
		Allocated polychemo.	Adjusted control		
(a) CMF regimens (including other non-anthracycline agents)					
73B INT Milan 7205	12 CMF	0/2082	0/1394		
75E2 Manchester I	12 CMF	0/434	0/436		
76C Glasgow	12 CMF	0/834	0/614		
76E EORTC 09771	24 CMF	0/1480	0/1233		
77B1+2 DanishBCG77bpre	12 CMF	0/2293	0/1741		
77G1 Vienna	36 CMFV	-/717	-/646	(no data)	
78E UK/Asia Collab.	12 CMF	0/1229	0/1095		
78K IBCSG Ludwig III post	12 CMF	0/1387	0/1082		
78V2 EOCG EST16177 post	12 CMFPr	0/548	0/596		
79B1 SWOG7827ApoER+	12 CMFVPr	0/2568	0/2380		
79C CaseWesternB ER+	12 CMFVPr	0/424	0/457		
79E Guy's/Manch. II	12 CMF	0/1536	0/1128		
79H Paris N-	6 CMF	-/1113	-/985	(no data)	
80F INTMilan 8004 N-	12 CMF	0/577	0/350		
80J1 Vienna Gyn. post	6 CMF	0/194	0/218		
80L SWOG 7985	?? CMFV			(no data)	
81H EST1180/SW.8294	6 CMFPr	0/2784	0/2283		
82C DanishBCG82cpost	9 CMF	0/4456	0/4197		
84D NCI-C MA.4	6 CMF	0/1771	0/1665		
85J1+3 PetrovStPetersb'g	4 CMF; 2TtMF	0/1840	0/1703		
86H2 IBCSG VII *	13/6 CMF	0/5706	3(0/1758)		
87D3 GABG 3 Germany	6 CMF	-/1066	-/916	(no data)	
88C NSABP B-20	?? CMF	0/6004	0/5784		
88D IBCSG IX	3 CMF	0/4335	0/4102		
89A2 SITAM-01	6 CMF	0/287	0/273		
89E4+9 GROCTA V Italy	6 CMF	0/213	0/168		
89J1 CRCRAMS Moscow	6 CMF	-/739	-/24	(no data)	
89V Romagnolo Italy	6 CMF	0/791	0/772		
90P Amsterdam C8913	6 CMF	-/633	-/452	(no data)	
90S1 IBCSG VIII	6 CMF			(no data)	
90X1 Tokyo CIH	6 CMF	0/611	0/634		
93S Hamburg, Germany	6 CMF	-/396	-/430	(no data)	
	Sweden-Finland	9 CMF		(no data)	
(a) subtotal with data *		0/44384	0/39579		
		(0.0%/y)	(0.0%/y)		
(b) Anthracycline regimens					
74D1 DFCI 74-063 *	7/3-5 AC	0/44	2(0/17)		
76H1 West Midlands N+	6 CMFVAFol	0/1607	0/1188		
76L1 Cologne	?? AC			(no data)	
80B3+4 N Sweden BCG	8 AC	0/619	0/501		
80C2 SESwed.BCGB post	6 AC	0/226	0/169		
80S1 Helsinki	8 FAC	0/307	0/257		
80Z Wessex	6 VAP/VAC	0/438	0/384		
82F MD Anders.8227 N-	4 FACVPr	0/436	0/407		
83B GROCTA I Italy ER+	6 CMF; 4 E	0/1449	0/1306		
84C NSABP B-16 post	24 MeIF±A/3AC	2/6746	2(0/3042)	0.5 0.4	
84Q4+5 Austrian BCSG 4	6 CMFVA	0/751	0/753		
86P2+3 FASG France	6 FAC	0/3164	0/2931		
89@ Bari Italy N-	6 FEC	0/643	0/534		
89B1 SWOG 8814 *	6 FAC	0/6781	4(0/2091)		
89D IGR Paris	6 FAC/FEC	0/3359	0/3075		
90C6 FASG GFEA 07	6 FEC	0/645	0/600		
92D Amsterdam C9203	4 EC	-/179	-/178	(no data)	
93H IBCSG 11-93 N+pre†	4 AC	0/305	0/302		
93M1+2 IBCSG 12-93 N+post	4 AC			(no data)	
94F JCOG 9401 N+post	6 AC	-/200	-/202	(no data)	
(b) subtotal with data *		2/27520	0/26909	0.5 0.4	
		(0.0%/y)	(0.0%/y)		3.86 (SE 3.35) increase 2p > 0.1; NS
(c) Other polychemotherapy					
73C1 Mayo 70-56-32	12 CFP	-/158	-/130	(no data)	
74E UK MCCG 003	6 CVF/CVM	0/709	0/568		
75G Northwick Park	12 MeIV	0/546	0/601		
76H2 West Midlands N-	6 ChIMF	0/2969	0/2879		
76K HD 1 W. Germany	24 ChIF	0/451	0/372		
76P King's CRC M/M	24 MeIM	0/799	0/726		
77E Oxford	24 MeIMF	0/764	0/586		
77W2 Montpellier	12 CVF			(no data)	
78M3 NCCTG-773051 post	10 CFP	0/565	0/597		
81E NSABP B-13 N-	11 MFFol	0/3805	0/3338		
86D1 UK Multicentre	6 CVF/CVM	0/349	0/322		
88C NSABP B-20	?? MFFol	1/6021	0/5784	0.5 0.3	
92B2 HE1092 Greece	6 CMzF	0/538	0/633		
93A1245 UKCCCR ABC	† various			(no data)	
(c) subtotal with data §		1/17516	0/16406	0.5 0.3	
		(0.0%/y)	(0.0%/y)		6.82 (SE 6.06) increase 2p > 0.1; NS
Total (a + b + c) *		3/89420	0/82894	1.0 0.7	
		(0.0%/y)	(0.0%/y)		4.803 (SE 3.006) increase 2p > 0.1; NS

■ 99% or ◁▷ 95% confidence intervals

0 0.5 1.0 1.5 2.0

Difference between treatment effects in 2 subtotals: $\chi^2 = 0.0$; 2p > 0.1; NS


Polychemo. better | Polychemo. worse
Treatment effect 2p > 0.1; NS, adverse


Difference between treatment effects in 2 trials: $\chi^2 = 0.0$; 2p > 0.1; NS

§ 9 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 4501; allocated control: 3963)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone





■ 99% or ◁▷ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 3.7$; $p > 0.1$; NS


Heterogeneity within subtotals: $\chi^2_{22} = 31.4$; $p = 0.09$


Heterogeneity between 25 trials: $\chi^2_{24} = 35.0$; $p = 0.07$

§ 9 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 4501; allocated control: 3963)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone





■ 99% or ◊ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2_2 = 0.8$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2_{41} = 37.0$; $p > 0.1$; NS

Heterogeneity between 44 trials: $\chi^2_{43} = 37.8$; $p > 0.1$; NS

0 0.5 1.0 1.5 2.0

Polychemo. better | Polychemo. worse

Treatment effect 2p > 0.1; NS, adverse

§ 9 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 4501; allocated control: 3963)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone